Adjusted pooled cohort analysis of the association of statin use with survival outcomes
| Pooled cohort . | OS . | PFS . | ||||
|---|---|---|---|---|---|---|
| Events/patients . | HR (95% CI) . | P value . | Events/patients . | HR (95% CI) . | P value . | |
| Statin use | ||||||
| No | 314/993 | 1 | 547/993 | 1 | ||
| Yes | 92/418 | 0.62 (0.48-0.79) | <.001 | 195/418 | 0.74 (0.62-0.89) | .001 |
| Beta-blockers use | ||||||
| No | 316/1089 | 1 | 583/1089 | 1 | ||
| Yes | 90/322 | 1.06 (0.82-1.36) | .670 | 159/322 | 1.06 (0.88-1.28) | .529 |
| Calcium channel blockers use | ||||||
| No | 349/1222 | 1 | 650/1222 | 1 | ||
| Yes | 57/189 | 1.04 (0.77-1.39) | .808 | 92/189 | 0.76 (0.61-0.96) | .023 |
| ACEI/ARBs use | ||||||
| No | 297/1003 | 1 | 548/1003 | 1 | ||
| Yes | 109/408 | 1.11 (0.87-1.43) | .409 | 194/408 | 0.94 (0.78-1.13) | .506 |
| Diuretics use | ||||||
| No | 341/1169 | 1 | 623/1169 | 1 | ||
| Yes | 65/242 | 0.96 (0.72-1.30) | .809 | 119/242 | 1.04 (0.83-1.31) | .713 |
| SLL diagnosis | ||||||
| No | 37/1298 | 1 | 682/1298 | 1 | ||
| Yes | 34/113 | 1.11 (0.78-1.59) | .564 | 60/113 | 1.06 (0.81-1.40) | .668 |
| Sex (female) | ||||||
| No | 281/918 | 1 | 515/918 | 1 | ||
| Yes | 125/493 | 0.65 (0.52-0.83) | <.001 | 227/493 | 0.69 (0.58-0.82) | <.001 |
| Bulky disease | ||||||
| No | 163/718 | 1 | 322/718 | 1 | ||
| Yes | 243/693 | 1.46 (1.19-1.79) | <.001 | 420/693 | 1.56 (1.34-1.82) | <.001 |
| ECOG PS | ||||||
| 0 | 144/609 | 1 | 304/609 | 1 | ||
| ≥1 | 262/802 | 1.50 (1.21-1.85) | <.001 | 438/802 | 1.19 (1.03-1.39) | .022 |
| Weight | — | 0.99 (0.98-1.00) | .005 | — | 0.99 (0.99-1.00) | .015 |
| Age | — | 1.02 (1.01-1.03) | .004 | — | 1.00 (0.99-1.01) | .853 |
| Time since initial diagnosis | — | 1.00 (1.00-1.00) | .813 | — | 1.00 (1.00-1.00) | .215 |
| Comorbidity count | — | 1.00 (0.99-1.01) | .888 | — | 1.00 (1.00-1.01) | .348 |
| Pooled cohort . | OS . | PFS . | ||||
|---|---|---|---|---|---|---|
| Events/patients . | HR (95% CI) . | P value . | Events/patients . | HR (95% CI) . | P value . | |
| Statin use | ||||||
| No | 314/993 | 1 | 547/993 | 1 | ||
| Yes | 92/418 | 0.62 (0.48-0.79) | <.001 | 195/418 | 0.74 (0.62-0.89) | .001 |
| Beta-blockers use | ||||||
| No | 316/1089 | 1 | 583/1089 | 1 | ||
| Yes | 90/322 | 1.06 (0.82-1.36) | .670 | 159/322 | 1.06 (0.88-1.28) | .529 |
| Calcium channel blockers use | ||||||
| No | 349/1222 | 1 | 650/1222 | 1 | ||
| Yes | 57/189 | 1.04 (0.77-1.39) | .808 | 92/189 | 0.76 (0.61-0.96) | .023 |
| ACEI/ARBs use | ||||||
| No | 297/1003 | 1 | 548/1003 | 1 | ||
| Yes | 109/408 | 1.11 (0.87-1.43) | .409 | 194/408 | 0.94 (0.78-1.13) | .506 |
| Diuretics use | ||||||
| No | 341/1169 | 1 | 623/1169 | 1 | ||
| Yes | 65/242 | 0.96 (0.72-1.30) | .809 | 119/242 | 1.04 (0.83-1.31) | .713 |
| SLL diagnosis | ||||||
| No | 37/1298 | 1 | 682/1298 | 1 | ||
| Yes | 34/113 | 1.11 (0.78-1.59) | .564 | 60/113 | 1.06 (0.81-1.40) | .668 |
| Sex (female) | ||||||
| No | 281/918 | 1 | 515/918 | 1 | ||
| Yes | 125/493 | 0.65 (0.52-0.83) | <.001 | 227/493 | 0.69 (0.58-0.82) | <.001 |
| Bulky disease | ||||||
| No | 163/718 | 1 | 322/718 | 1 | ||
| Yes | 243/693 | 1.46 (1.19-1.79) | <.001 | 420/693 | 1.56 (1.34-1.82) | <.001 |
| ECOG PS | ||||||
| 0 | 144/609 | 1 | 304/609 | 1 | ||
| ≥1 | 262/802 | 1.50 (1.21-1.85) | <.001 | 438/802 | 1.19 (1.03-1.39) | .022 |
| Weight | — | 0.99 (0.98-1.00) | .005 | — | 0.99 (0.99-1.00) | .015 |
| Age | — | 1.02 (1.01-1.03) | .004 | — | 1.00 (0.99-1.01) | .853 |
| Time since initial diagnosis | — | 1.00 (1.00-1.00) | .813 | — | 1.00 (1.00-1.00) | .215 |
| Comorbidity count | — | 1.00 (0.99-1.01) | .888 | — | 1.00 (1.00-1.01) | .348 |
Adjustment variables: diagnosis, age, sex, weight, ECOG PS, bulky disease ≥5 cm, time since initial diagnosis, comorbidity count, use of beta-blockers, calcium channel blockers, ACEIs/ARBs, and diuretics.